Everolimus in Anaplastic Thyroid Cancer: A Case Series
Ethan Harris(University of Chicago), Jochen H. Lorch(Northwestern University), Glenn J. Hanna(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Matthew A. Nehs(Brigham and Women's Hospital), Phillip Groden(Icahn School of Medicine at Mount Sinai), Guilherme Rabinowits(Baptist Hospital of Miami), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Justine A. Barletta(Brigham and Women's Hospital), Roy B. Tishler(Dana-Farber Cancer Institute), Alec Kacew(Hospital of the University of Pennsylvania), Danielle N. Margalit(Harvard University), Robert I. Haddad(Georgetown University), Nicole G. Chau(University of British Columbia), Julian Huang(Yale University)
Cited by 41
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k